biote

Digital Health Expansion Will Elevate Preventative Care Despite Regulatory Hurdles

AnalystHighTarget

Not Invested

Community Contributor

Published

19 May 25

Updated

13 Dec 25

n/a

AnalystHighTarget's Fair Value

n/a

-57.6%

5.9%

-57.6%

5.9%

You can edit this narrative until Dec 14 3:10 PM. Then, changes will post as Updates.

Author's Valuation

US$655.0% undervalued

AnalystHighTarget Fair Value

Narrative

Updates1

Shared on 13 Dec 25

BTMD: Share Repurchases Will Support Future Upside In This Bullish Outlook

Analysts have modestly raised their price target on biote to reflect stronger expected revenue growth and a higher future earnings multiple, partially offset by more conservative margin and discount rate assumptions. What's in the News biote Corp.

AnalystHighTarget Fair Value

US$6

55.0% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

7.71%

Pharma revenue growth rate

0.63%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.96%

Calculation

US$4.48m

Earnings '28

55.77x

PE Ratio '28

US$249.60m

Market Cap '28

US$249.60m

Market Cap '28

34.73m

No. shares '28

US$7.19

Share Price '28

US$7.19 Share Price '28

Discounted to 2025 @ 6.96% p.a.

US$5.87

Fair Value '25